Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2003-03-04
2009-08-18
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
07576131
ABSTRACT:
The present invention provides the use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.
REFERENCES:
patent: 3378582 (1968-04-01), Bolhofer
patent: 3517050 (1970-06-01), Bolhofer
patent: 3517051 (1970-06-01), Bolhofer
patent: 3860628 (1975-01-01), Shuman
patent: 3923855 (1975-12-01), Shuman
patent: 3953490 (1976-04-01), Shuman
patent: 4067996 (1978-01-01), Najer et al.
patent: 4146623 (1979-03-01), Parker
patent: 4250191 (1981-02-01), Edwards
patent: 4532135 (1985-07-01), Edwards
patent: 4933367 (1990-06-01), Wolff et al.
patent: 5716987 (1998-02-01), Wille
patent: 5726987 (1998-03-01), Uriu
patent: 5859051 (1999-01-01), Adams et al.
patent: 5883124 (1999-03-01), Samid
patent: 6028052 (2000-02-01), Heyman et al.
patent: 6262118 (2001-07-01), Luskey et al.
patent: 6555577 (2003-04-01), Mogensen et al.
patent: 6576662 (2003-06-01), Nanduri et al.
patent: 6613802 (2003-09-01), Luskey et al.
patent: 6624194 (2003-09-01), Luskey et al.
patent: 6646004 (2003-11-01), Luskey et al.
patent: 6670395 (2003-12-01), Wille
patent: 6693094 (2004-02-01), Pearson et al.
patent: 7335671 (2008-02-01), Stapper et al.
patent: 7355069 (2008-04-01), Li
patent: 2003/0220399 (2003-11-01), Luskey et al.
patent: 2004/0039053 (2004-02-01), Luskey et al.
patent: 2004/0204472 (2004-10-01), Briggs
patent: 2005/0033084 (2005-02-01), Daugs
patent: 2007/0207983 (2007-09-01), Nieuwenhuizen et al.
patent: 2007/0248590 (2007-10-01), Milne et al.
patent: 2008/0027121 (2008-01-01), Laudon et al.
patent: 967978 (1975-05-01), None
patent: 1476525 (1967-04-01), None
patent: 1182008 (1970-02-01), None
patent: 1403309 (1975-08-01), None
patent: WO 92/17435 (1992-10-01), None
patent: WO 00/74666 (2000-12-01), None
patent: WO 02/44113 (2002-06-01), None
patent: WO 2004/112774 (2004-12-01), None
Diamant et al. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs, 2003, vol. 63, pp. 1373-1405. Abstract attached.
“Insulin Resistance” accessed from the internet (http://syndromex.stanford.edu/InsulinResistance.htm) on Jul. 25, 2008.
Aronow, W.S. et al., “Effect of halofenate on serum lipids,”Clin. Pharmacol. Ther., 14:358-365 (1973).
Aronow, W.S. et al., “Halofenate: An Effective Hypolipemia- and Hypouricemia-Inducing Drug,”Current Therapeutic Research, 15:902-906 (1973).
Barrett-Connor, “Epidemiology, Obesity, and Non-Insulin-Dependent Diabetes Mellitus,”Epidemiologic Review, 11:172-181 (1989).
Bassett, D.R. et al., “Effects of halofenate and probenecid in serum lipids and uric acid in hyperlipidemic, hyperuricemic adults,”Clin. Pharmacol. Ther., 22:340-351 (1977).
Bell, G.I. et al., “Glucokinase Mutations, Insulin Secretion, and Diabetes Mellitus,”Annu. Rev. Physiol., 58:171-186 (1996).
Berkow, R., “The Merck Manual of Diagnosis and Therapy—15th Edition,” pp. 1069-1072, Merck Research Laboratories, N.J. (1987).
Bluestone, R. et al., “Halofenate—Its Selection and Trial as a Primary Uricosuric Agent,”Arthritis Rheum., 18:859-862 (1975).
Brooks, D. A. et al., “Design and Synthesis of 2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy} propionic Acids: A New Class of Dual PPARaly Agonists,”J. Med. Chem.,44:2061-2064 (2001).
Chiasson, J. et al., “The Efficacy of Acarbose in the Treatment of Patients with Non-Insulin-dependant Diabetes Mellitus,”Ann. Intern. Med., 121:928-935 (1994).
Coniff, R. et al., “Multicenter, Placebo-Controlled Trial Comparing Acarbose (BAY g 5421) With Placebo, Tolbutamide, and Tolbutamide-Plus-Acarbose in Non-Insulin-Dependent Diabetes Mellitus,”The American Journal of Medicine, 98:443-451 (1995).
Coniff, R. et al., “Acarbose: A Review of US Clinical Experience,”Clinical Therapeutics, 19:16-26 (1997).
Dorfler, H. et al., “Primarer Verteilungsraum und Plasmahalbwertszeit von intravenous verabreichtem Insulin,”Med. Poliklinik Univ. Muchenpp. 1297-1299.
Edelman, S.V. et al., “Non-Insulin-Dependent Diabetes Mellitus,”Current Therapy in Endocrinology and Metabolism, pp. 430-438 (1997).
Fajans, S.S. et al., “Maturity Onset Diabetes of the Young (MODY),”Diabetes Medicine, 13:S90-S95 (1996).
Fanelli, G.M., Jr. “Renal Excretion and Uricosuric Properties of Halofenate A Hypolipidemic Uricosuric Agent in the Chimpanzee,”J. Pharmacol. Exp. Ther., 180:377-396 (1972).
Feldman, E.B., et al., “Insulin Sensitivity in Hypertriglyceridemia: induction by combined triglyceride and uric lowering”, Clinical Research vo. 23, No. 1, p. 43A (1975).
Feldman, E.B., et al., “Effects of Halofenate on Glucose Tolerance in Patients with Hyperlipoproteinemia,” Journal Clinical Pharmacology, 18:241-248 (1978) May-Jun. 1978.
Flier, J.S., “Insulin Receptors and Insulin Resistance,”Ann. Rev. Med., 34:145-160 (1983).
Friedberg,, S.J., “The Control of Insulin Resistant and Refractory Type II Diabetes Mellitus by Means of Halofenate-Sulfonylurea Combined Regimen,”Clinical Research, 34:682A (1986).
Gavin III, J.R. et al., “Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus,”Diabetes Care, 22:S5-S19 (1999).
Goetze S. et al., “PPARγ-Ligands Inhibit Migration Mediated by Multiple Chemoattractants in Vascular Smooth Muscle Cells,”Journal of Cardiovascular Pharmacology, 33:798-806 (1999).
Howard, B.V. et al., “Lipoprotein Composition in Diabetes Mellitus,”Atherosclerosis, 30:153-162 (1978).
Hucker, H.B. et al., “Metabolism of a New Hypolipidemic Agent, 2-Acetamidoethyl (p-Chlorophenyl) (m-Trifluoromethylphenoxy)-Acetate (Halofenate) in the Rat, Dog, Rhesus Monkey and Man,”The Journal of Pharmacology and Experimental Therapeutics, 179:359-371 (1971).
Hutchison, J.C. et al., “The Uricosuric Action of Halofenate (MK-185) in Patients with Hyperuricemia or Uncomplicated Primary Gout and Hyperlipidemia,”Atherosclerosis, 18:353-362 (1973).
Iwamoto, Y. et al., “Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy Alone,”Diabetic Medicine, 13:365-370 (1996).
Jain, A. et al., “The effect of MK-185 on some aspects of uric acid metabolism,”Clin. Pharmacol. Ther., 11:551-557 (1970).
Jain, A. et al., “Potentiation of Hypoglycemic Effect of Sulfonylureas by Halofenate,”New England J. of Med. 293:25, pp. 1283-1286 (1975).
Joslin, E.P., “Arteriosclerosis and Diabetes,”Annals of Clinical Medicine, 5:1061-1079 (1927).
Keller, V.C. et al., “Die Behandung von Hyperlipidamie und Hyperurikamie mit 2-Acetamidoathyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetat (Halofenat), einem Derivat des Clofibrat,” Arzneim-Forsch. (Drug Res.) 26:2221-2224 (1976).
Knowler, W. C. et al., “Obesity in the Pima Indians: its magnitude and relationship with diabetes,”Am J Clin Nutr, 53:1543S-1551S (1991).
Kobayashi, M. et al., “Improvement of Glucose Tolerance in NIDDM by Clofibrate,”Diabetes Care, 11:6, pp. 495-499 (1988).
Kohle, E. A. et al., “Improved Control of Non-insulin-dependent Diabetes Mellitus by Combined Halofenate and Chlorpropamide Therapy,”Diabetes Care, 7:19-24 (1984).
Kreisberg, R.A., “Hyperlipidemia,”Curr. Therapy Endocrin. Metabol., 6th Ed., pp. 509-519; Mosby-Yearbook, Inc. (1997).
Krut, L. H. et al., “Comparison of Clofibrate with Halofenate in Diabetics with Hyperlipidaemia,”S. A. Med. J., pp. 348-352 (1977).
Kuntznen, V.O. et al., “Wirkung von Halofenat auf Triglycerid-und Hamsaurespiegel sowie auf Gerinnungs- und Thrombozytenverhalten bei Patienten mit Hyperlipoproteinamie Typ IV und Hyperurikamie,” Arzneim-Forsch. (Drug Res)., 28:2349-2352 (1978).
Luo Jian
Luskey Kenneth L.
Anderson James D
DiaTex, Inc.
Metabolex Inc.
Townsend and Townsend / and Crew LLP
LandOfFree
Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103631